Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Timing of NM283 SVR data:

SVR data from the NM283 phase-2b trial in the treatment-naïve setting should just barely be available for the first patients who enrolled. July 2005 + 72 weeks = Dec 2006; adding a couple of months for database lock and analysis takes us to right now.

As enrollment in this trial was not completed until Jan 2006, the complete SVR data will not be available until around Aug 2007. Moreover, enrollment in most trials is back-ended, so the SVR data available now are apt to be scant.

Conclusion: PJ may well have some anecdotal information indicating a low rate of SVR, but they cannot possibly have the whole story.